The team behind Clinical Conductor CTMS recently debuted new functionality that allows healthcare organizations to better manage adaptive and dynamic clinical research that is becoming more relevant in the industry every year.
The team behind Clinical Conductor CTMS recently debuted new functionality that allows healthcare organizations to better manage adaptive and dynamic clinical research that is becoming more relevant in the industry every year.
This quarter, the development team has added unique features including:
· Budget snapshots for better financial management and negotiations with sponsors
· The ability for organizations to create multiple charge masters
· Protocol versioning – where organizations can create new versions of a protocol and more easily handle amendments that occur
All of these features help solve an existing problem in research where technology can sometimes be lacking: flexibility. Since research is continuously changing, researchers and managers need technology capable of providing the granular data they need to remain profitable and produce high quality clinical research.
Truqap Combination Shines in Phase III Trial for Prostate Cancer
November 26th 2024Data from the CAPItello-281 trial show Truqap alongside abiraterone and androgen deprivation therapy achieved a statistically significant and clinically meaningful improvement in radiographic progression-free survival.
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.